An increase or decrease in CA125 levels correlated with disease progression or regression in 93% of cases, which suggested that CA125 might be helpful in monitoring response to treatment in patients with epithelial ovarian cancer [9,10]. Here, MUC16 is linked to ovarian carcinoma.